CO2019012356A2 - Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso - Google Patents

Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso

Info

Publication number
CO2019012356A2
CO2019012356A2 CONC2019/0012356A CO2019012356A CO2019012356A2 CO 2019012356 A2 CO2019012356 A2 CO 2019012356A2 CO 2019012356 A CO2019012356 A CO 2019012356A CO 2019012356 A2 CO2019012356 A2 CO 2019012356A2
Authority
CO
Colombia
Prior art keywords
antibodies
methods
programmed death
death receptor
combination
Prior art date
Application number
CONC2019/0012356A
Other languages
English (en)
Spanish (es)
Inventor
Arnab De
Chakravarthy Nachu Narasimhan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64016405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019012356(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CO2019012356A2 publication Critical patent/CO2019012356A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CONC2019/0012356A 2017-05-02 2019-11-01 Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso CO2019012356A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500278P 2017-05-02 2017-05-02
PCT/US2018/030516 WO2018204405A1 (en) 2017-05-02 2018-05-01 Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2019012356A2 true CO2019012356A2 (es) 2020-01-17

Family

ID=64016405

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0012356A CO2019012356A2 (es) 2017-05-02 2019-11-01 Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso

Country Status (15)

Country Link
US (2) US20200354453A1 (cg-RX-API-DMAC7.html)
EP (1) EP3618855A4 (cg-RX-API-DMAC7.html)
JP (2) JP7402693B2 (cg-RX-API-DMAC7.html)
KR (1) KR102770786B1 (cg-RX-API-DMAC7.html)
CN (1) CN110603052A (cg-RX-API-DMAC7.html)
AU (1) AU2018261080A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019022698A2 (cg-RX-API-DMAC7.html)
CA (1) CA3061050A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003145A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012356A2 (cg-RX-API-DMAC7.html)
IL (1) IL270175B2 (cg-RX-API-DMAC7.html)
MA (1) MA50661A (cg-RX-API-DMAC7.html)
MX (1) MX2019013033A (cg-RX-API-DMAC7.html)
SG (2) SG11201909941QA (cg-RX-API-DMAC7.html)
WO (1) WO2018204405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN115925931A (zh) * 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体および抗pd-1抗体の共-製剤
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2021007047A (es) * 2018-12-14 2021-10-26 Morphosys Ag Formulaciones de anticuerpos.
CA3139641A1 (en) * 2019-06-13 2020-12-17 Green Cross Corporation Antibody to tigit and use thereof
EP3999537A1 (en) * 2019-07-19 2022-05-25 Ichnos Sciences SA Lyophilized antibody formulation
CN112741804A (zh) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
CN115052622B (zh) * 2020-01-21 2026-03-06 夏尔巴生物技术(杭州)有限公司 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
MX2022008949A (es) * 2020-01-24 2022-08-15 Regeneron Pharma Formulacion de anticuerpos estable.
CN111995681B (zh) * 2020-05-09 2022-03-08 华博生物医药技术(上海)有限公司 抗tigit的抗体、其制备方法和应用
TW202210514A (zh) * 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CN111718415B (zh) * 2020-07-03 2021-02-23 上海洛启生物医药技术有限公司 一种抗tigit纳米抗体及其应用
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
JP2023539736A (ja) * 2020-08-25 2023-09-19 ブリストル-マイヤーズ スクイブ カンパニー 拮抗性cd40モノクローナル抗体で自己免疫性疾患を処置する方法
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
PT4267105T (pt) * 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
EP4293045A4 (en) * 2021-01-14 2024-12-11 Shanghai Junshi Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION OF ANTI-TIGIT ANTIBODY AND ITS APPLICATION
AU2022212007A1 (en) 2021-01-29 2023-09-07 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CA3217279A1 (en) 2021-05-04 2022-11-10 Olga Ignatovich Anti-tigit antibodies and methods of use thereof
US20240352153A1 (en) * 2021-07-23 2024-10-24 Akeso Biopharma, Inc Pharmaceutical composition and use
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN114106182B (zh) * 2022-01-26 2022-05-17 中山康方生物医药有限公司 抗tigit的抗体及其用途
WO2023163968A1 (en) * 2022-02-24 2023-08-31 Merck Sharp & Dohme Llc Stable formulations of a multivalent vhh based cytotoxic t lymphocyte associated antigen 4 (ctla4) binder binding to human ctla4 and methods of use thereof
TW202345902A (zh) * 2022-04-14 2023-12-01 瑞士商百濟神州瑞士有限責任公司 含有pd-1抗體的穩定高濃度精胺酸配製物及其使用方法
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック, インコーポレイテッド 抗pd-l1アンタゴニストおよび抗tigitアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
WO2024030458A2 (en) * 2022-08-04 2024-02-08 Merck Sharp & Dohme Llc Methods for determining one or more critical quality attributes of co-formulated antibodies
JP2026502936A (ja) * 2022-12-27 2026-01-27 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗tigit抗体を含む医薬製剤
WO2025166550A1 (zh) * 2024-02-06 2025-08-14 香港北恒生物科技有限公司 工程化细胞及其用途
CN121003695A (zh) * 2024-05-24 2025-11-25 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
WO2025248110A1 (en) 2024-05-31 2025-12-04 Replimune Limited An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
WO2011008770A2 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
WO2012135408A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
CA2957722C (en) * 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
CA2998589A1 (en) * 2015-09-14 2017-03-23 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.
EP3394099A4 (en) * 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations of Manipulated Anti- IL-10 Antibodies
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン,エルエルシー 抗pd−l1および抗ctla−4抗体の共製剤を含む組成物
CA3060695A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Also Published As

Publication number Publication date
KR102770786B1 (ko) 2025-02-20
CN110603052A (zh) 2019-12-20
KR20190142394A (ko) 2019-12-26
SG11201909941QA (en) 2019-11-28
CA3061050A1 (en) 2018-11-08
EP3618855A1 (en) 2020-03-11
US20200354453A1 (en) 2020-11-12
BR112019022698A2 (pt) 2020-05-19
IL270175A (cg-RX-API-DMAC7.html) 2019-12-31
JP7402693B2 (ja) 2023-12-21
IL270175B1 (en) 2023-05-01
AU2018261080A1 (en) 2019-11-07
RU2019138519A (ru) 2021-06-02
EP3618855A4 (en) 2021-02-17
CL2019003145A1 (es) 2020-07-10
SG10202111905PA (en) 2021-12-30
RU2019138519A3 (cg-RX-API-DMAC7.html) 2021-08-30
US20240182573A1 (en) 2024-06-06
MA50661A (fr) 2020-08-05
JP2020518600A (ja) 2020-06-25
MX2019013033A (es) 2020-02-05
WO2018204405A1 (en) 2018-11-08
IL270175B2 (en) 2023-09-01
JP2024016177A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
CL2019003145A1 (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso.
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2023001091A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
ECSP19078414A (es) Anticuerpos anti-cd33 y métodos para utilizarlos
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
IL280467A (en) Antibody constructs for cldn18.2 and cd3
MX2019011927A (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
MX390920B (es) Moléculas de unión a lag-3 y métodos de uso de las mismas.
MX2020012639A (es) Anticuerpos frente a entpd2, terapias de combinacion y metodos de uso de los anticuerpos y las terapias de combinacion.
CO2021001742A2 (es) Anticuerpos anti–sortilina y métodos para su uso
CL2021000736A1 (es) Receptor de antígeno quimérico.
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
MX374853B (es) Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso.
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
AR112401A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos
AR122237A1 (es) Anticuerpos anti-sortilina y métodos para su uso